Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 in Combination With Paclitaxel in Second-line Small Cell Lung Cancer
NCT06616532Phase 3Active, not recruiting
- Sponsor
- Biotheus
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig in small cell lung cancer (SCLC), sponsored by Biotheus. Started Nov 2024; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06616532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616532.